#India #Mumbai #CDMO #Piramal Pharma #ICH

Piramal Pharma Limited's Financial Highlights for FY25

Piramal Pharma Limited has announced strong financial results for the third quarter and the first nine months of the fiscal year 2025, reflecting a robust performance in the pharmaceutical and wellness industry. The firm reported remarkable growth across major business segments driven by operational efficiency and strategic innovations.

Financial Overview

In the financial figures for the third quarter (Q3 FY25) and the first nine months (9M FY25), the consolidated operating revenue reached ₹2,204 crores in Q3 FY25, marking a 13% increase from ₹1,959 crores in Q3 FY24. For the first nine months, the revenue was ₹6,397 crores, representing a 14% growth against ₹5,619 crores in the previous fiscal year.

Key Performance Indicators

• - CDMO Revenue: The Contract Development and Manufacturing Organization segment posted revenues of ₹1,278 crores for Q3, which is a 13% year-on-year increase and ₹3,659 crores for 9M FY25, up 18% from ₹3,101 crores in FY24.
• - Healthcare Generics Growth: The Complex Hospital Generics (CHG) sector saw a promising increase of 14% year-on-year for Q3 and 8% for the first nine months. This growth is significantly attributable to the rising volume in anesthetic products over the period.
• - Consumer Healthcare Growth: The India Consumer Healthcare (ICH) segment continued its upward trajectory with a stellar growth rate of 19%, contributing positively to the overall performance of the company.

Sustainability Initiatives

Piramal Pharma Limited is committed to sustainable business practices alongside its strong financial gains. A notable highlight for FY25 was the transition of its coal-powered steam boiler at the Digwal facility to biomass briquettes, a move expected to cut greenhouse gas emissions by approximately 24,000 tons of CO2 equivalent annually. This initiative not only shows great environmental responsibility but also positions the company as a leader in sustainable practices within the pharmaceutical industry.

Leadership Vision

Nandini Piramal, the chairperson of Piramal Pharma Limited, highlighted the balanced progress during the fiscal year, stating, "We have seen a stable year so far in FY25, with a 14% revenue growth. Our CDMO operations remain strong with an 18% revenue increase across nine months. This performance comes from our unwavering commitment to innovation and excellence in operations."

The company maintained a debt-to-EBITDA ratio of 2.8 times, showcasing its strong balance sheet and financial prudence. Despite various market challenges, the firm continues to excel while reinforcing its commitment to sustainability and operational excellence across all its business units.

Future Outlook

As Piramal Pharma Limited moves forward, it aims to leverage its growth strategies, particularly in expanding its production capabilities and fortifying its market position in both hospital generics and consumer healthcare sectors. With continued innovation and expansion efforts, the company is set to not only fulfill its business objectives but also contribute positively towards healthcare advancements and environmental sustainability.

In conclusion, Piramal Pharma Limited's focus on robust financial results, alongside a strong commitment to sustainable practices, illustrates its dual objective of achieving business success while being responsible stewards of health and the environment.